Emerging Pharmaceutical Therapies to Address the Inadequacy of a Gluten-Free Diet for Celiac Disease.
Study Goal
The researchers aimed to outline the limitations of a gluten-free diet (GFD) for celiac disease (CeD) and explore potential non-dietary treatments.
Results Summary
The study highlights that a GFD, while the only current treatment for CeD, can be burdensome and may not fully resolve symptoms or mucosal injury, leading to psychological impacts and reduced quality of life. It also discusses recent advances in pharmaceutical treatments for CeD.
Population
Adult patients with celiac disease experiencing ongoing symptoms and persistent duodenal villous atrophy.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
gluten-free diet (GFD) | no change | symptoms and mucosal injury | patients with Celiac disease (CeD) | persist | can cause a significant burden | #1 |
gluten-free diet (GFD) | decrease | quality of life | patients with Celiac disease (CeD) | - | affect | #2 |
pharmaceutical treatments specific to CeD | neutral | non-dietary treatment of CeD | adult patients on a GFD who experience ongoing symptoms attributed to CeD and also show persistent duodenal villous atrophy | - | feasible to explore | #3 |
Celiac disease (CeD) is a chronic autoimmune disorder triggered by the ingestion of gluten, affecting around 1% of the global population. It is a multifactorial disease involving both genetics and environmental factors. Nowadays, the only available treatment for CeD is a life-long gluten-free diet (GFD), which can cause a significant burden for patients, since symptoms and mucosal injury can persist despite apparent compliance with a GFD. This could also lead to psychological consequences and affect the quality of life of these patients. Thankfully, recent advances in understanding the pathogenesis of CeD and the availability of various targets have made it feasible to explore pharmaceutical treatments specific to CeD. Recently, the FDA has highlighted the unmet needs of adult patients on a GFD who experience ongoing symptoms attributed to CeD and also show persistent duodenal villous atrophy. This review will outline the limitations of a GFD, describe the targets of potential novel treatment of CeD and provide an overview of the primary clinical trials involving oral and injectable agents for a non-dietary treatment of CeD.